Bli medlem
Bli medlem

Du är här

2016-12-20

Medigene AG: Medigene announces outlicensing of AAVLP technology

Medigene AG / Medigene announces outlicensing of AAVLP technology. Processed
and transmitted by Nasdaq Corporate Solutions. The issuer is solely
responsible for the content of this announcement.
2A Pharma AB to continue development of AAVLP based vaccines

Martinsried/Munich, 20 December 2016.
Medigene AG(FSE: MDG1, Prime Standard, TecDAX) announced today that it has
granted an exclusive, worldwide license for the development and
commercialization of its preclinical stage adeno-associated virus like
particles (AAVLPs) technology to the Swedish biotech company 2A Pharma AB,
located in Malmö, Sweden. Under the terms of the agreement, Medigene is
eligible to receive clinical, regulatory and commercial milestone payments in
addition to royalties on net sales of future AAVLP products by 2A Pharma AB.
Further financial details were not disclosed.

The AAVLP technology is unrelated to Medigene's current immunotherapy programs
and was a former research project at Medigene before its repositioning as a T
cell immunotherapy company.

Dave Lemus, COO of Medigene AG,
comments: "We are pleased to have created a new future for our AAVLP platform
at a promising young biotech company which is wholly focused and dedicated to
successfully developing this vaccine technology. While Medigene will
potentially benefit from its future progress, we will continue to concentrate
on our core business, especially the development of T-cell receptor (TCR)
modified T cells and next generation dendritic cell (DC) vaccines."

Prof. Søren Nielsen, CEO of 2A Pharma AB,
adds: "We founded 2A Pharma AB in order to further develop this very
interesting AAVLP technology. We are convinced of the future potential of the
same as an innovative therapy and we are pleased that we have attracted
investors who will provide us sufficient funding to reach the clinical
development stage."

About AAVLP
: AAVLPs offer the potential to develop vaccines against various indications,
including cancer and infectious diseases. The adeno-associated virus is
non-pathogenic, and the virus protein shell, the capsid, is well-suited for
the production of virus-like particles (VLPs), as a basis for novel vaccines.

AAVLPs have previously been developed as B-cell vaccines. Peptides inserted in
the capsid can induce a humoral immune response (B-cell induction and
antibody production). First preclinical tests with AAVLPs were conducted by
academic partners of Medigene AG.

About 2A Pharma AB:
2A Pharma AB was newly founded as a limited liability company in December 2016
in Malmö, Sweden, with Prof. Søren Nielsen as CEO, Preben Bruun Nyzell as CFO
and Dr. John Nieland as COO, as a start-up biotech company with the aim to
develop novel vaccine products. Strong private investors participated in the
company's first financing round.

Medigene AG
(FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed
biotechnology company headquartered in Martinsried near Munich, Germany. The
company is developing highly innovative, complementary treatment platforms to
target various types and stages of cancer with candidates in clinical and
pre-clinical development. Medigene concentrates on the development of
personalized T cell-based immunotherapies.

For more information, please visitwww.medigene.com

This press release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual results
achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these
forward-looking statements. Medigene®is a registered trademark of Medigene
AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG

Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email:investor@medigene.com

Kontakt 2A Pharma AB

Søren Nielsen
CEO, Prof.Dr.
2A Pharma AB
Malmoe, Sweden
Tel: +45 2539 4137
Email:sn@2apharma.com

In case you no longer wish to receive any information about Medigene, please
inform us by e-mail (investor@medigene.com). We will then delete your address
from our distribution list.

press release AAVLP
http://hugin.info/132073/R/2066417/775764.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.